Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,218.00
(
1.73%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
97.72
(
1.03%
)
Bitcoin
78,310.76
(
0.09%
)
News Focus
News Focus
Post# of 257438
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 213658

Tuesday, 09/18/2018 5:06:18 PM

Tuesday, September 18, 2018 5:06:18 PM

Post# of 257438
BAVA.CO starts phase-2 of CV301+Tecentriq in bladder cancer:

https://globenewswire.com/news-release/2018/09/18/1572694/0/en/Bavarian-Nordic-Announces-Initiation-of-Phase-2-Trial-Evaluating-the-Combination-Therapy-of-CV301-and-Atezolizumab-in-Bladder-Cancer.html

Will CV301, which targets CEA and MUC1, work any better than ProstVac (#msg-134628335)? I don’t know, but the idea of targeting tumor-associated antigens rather than tumor neoantigens seems old fashioned.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today